Immuneering Stock Soars 25.74% on Promising Cancer Trial Results

On June 17, 2025, Immuneering's stock surged by 25.74% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.

Immuneering's Phase 2a trial for IMM-1-104 in patients with advanced solid tumors, including pancreatic cancer, has shown promising results. The trial revealed a 94% 6-month survival rate for atebimetinib, a breakthrough that outperforms current treatments. This positive outcome has generated substantial interest and excitement among investors and the medical community.

To discuss these groundbreaking findings, Immuneering Corporation will host a conference call on June 17, 2025. The call will provide updates on the ongoing Phase 2a clinical trial of IMM-1-104, focusing on first-line pancreatic cancer patients. The company aims to share interim data and insights from the trial, further solidifying its position as a leader in oncology research and development.